These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 18695118)

  • 1. Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study.
    Kong L; Mintz-Hittner HA; Penland RL; Kretzer FL; Chévez-Barrios P
    Arch Ophthalmol; 2008 Aug; 126(8):1161-3. PubMed ID: 18695118
    [No Abstract]   [Full Text] [Related]  

  • 2. Off-label use of bevacizumab in retinopathy of prematurity.
    Rishi E; Rishi P; Ratra D; Bhende M
    Retina; 2009 Feb; 29(2):284; author reply 284-5. PubMed ID: 18854784
    [No Abstract]   [Full Text] [Related]  

  • 3. Fluorescein angiography of recurrent retinopathy of prematurity after initial intravitreous bevacizumab treatment.
    Hoang QV; Kiernan DF; Chau FY; Shapiro MJ; Blair MP
    Arch Ophthalmol; 2010 Aug; 128(8):1080-1. PubMed ID: 20697016
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of type 1 retinopathy of prematurity with intravitreal bevacizumab (Avastin).
    Dorta P; Kychenthal A
    Retina; 2010 Apr; 30(4 Suppl):S24-31. PubMed ID: 20224475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concentration of vascular endothelial growth factor in aqueous humor of eyes with advanced retinopathy of prematurity before and after intravitreal injection of bevacizumab.
    Nonobe NI; Kachi S; Kondo M; Takai Y; Takemoto K; Nakayama A; Hayakawa M; Terasaki H
    Retina; 2009 May; 29(5):579-85. PubMed ID: 19430279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significant treatment failure with intravitreous bevacizumab for retinopathy of prematurity.
    Patel RD; Blair MP; Shapiro MJ; Lichtenstein SJ
    Arch Ophthalmol; 2012 Jun; 130(6):801-2. PubMed ID: 22801851
    [No Abstract]   [Full Text] [Related]  

  • 7. Bilateral effect of unilateral bevacizumab injection in retinopathy of prematurity.
    Karaca C; Oner AO; Mirza E; Polat OA; Sahiner M
    JAMA Ophthalmol; 2013 Aug; 131(8):1099-101. PubMed ID: 23744183
    [No Abstract]   [Full Text] [Related]  

  • 8. Vitrectomy after intravitreal bevacizumab (Avastin) for retinal detachment in retinopathy of prematurity.
    Kychenthal A; Dorta P
    Retina; 2010 Apr; 30(4 Suppl):S32-6. PubMed ID: 20224474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early refractive outcome after intravitreous bevacizumab for retinopathy of prematurity.
    Harder BC; von Baltz S; Schlichtenbrede FC; Jonas JB
    Arch Ophthalmol; 2012 Jun; 130(6):800-1. PubMed ID: 22801850
    [No Abstract]   [Full Text] [Related]  

  • 10. Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II.
    Mintz-Hittner HA; Kuffel RR
    Retina; 2008 Jun; 28(6):831-8. PubMed ID: 18536599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ultra-low dose of intravitreal bevacizumab in the treatment of retinopathy of prematurity.
    Connor AJ; Papastavrou VT; Hillier RJ; Shafiq A
    J Pediatr Ophthalmol Strabismus; 2015 Apr; 52 Online():e20-1. PubMed ID: 25942065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab for retinopathy of prematurity.
    Lim LS; Mitchell P; Wong TY
    N Engl J Med; 2011 Jun; 364(24):2360; author reply 2361-2. PubMed ID: 21675897
    [No Abstract]   [Full Text] [Related]  

  • 13. Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity.
    Travassos A; Teixeira S; Ferreira P; Regadas I; Travassos AS; Esperancinha FE; Prieto I; Pires G; van Velze R; Valido A; Machado Mdo C
    Ophthalmic Surg Lasers Imaging; 2007; 38(3):233-7. PubMed ID: 17552391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity.
    Sato T; Kusaka S; Shimojo H; Fujikado T
    Ophthalmology; 2009 Sep; 116(9):1599-603. PubMed ID: 19371954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [VEGF antibodies as therapy for retinopathy of prematurity].
    Oberacher-Velten IM; Helbig H
    Klin Monbl Augenheilkd; 2010 Sep; 227(9):694-700. PubMed ID: 20845249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A rare association of intravitreal bevacizumab injection with double ridge formation in retinopathy of prematurity.
    Yaz Y; Erol N; Gursoy H; Basmak H; Bilgec MD
    J Pediatr Ophthalmol Strabismus; 2014 Oct; 51 Online():e66-8. PubMed ID: 25333243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitreous levels of angiopoietin-1 and angiopoietin-2 in eyes with retinopathy of prematurity.
    Sato T; Shima C; Kusaka S
    Am J Ophthalmol; 2011 Feb; 151(2):353-7.e1. PubMed ID: 21168819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab for retinopathy of prematurity.
    Gilbert CE; Zin A; Darlow B
    N Engl J Med; 2011 Jun; 364(24):2359-60; author reply 2361-2. PubMed ID: 21675898
    [No Abstract]   [Full Text] [Related]  

  • 19. Intravitreal bevacizumab following laser therapy for severe retinopathy of prematurity.
    Erol N; Gürsoy H; Sahin A; Basmak H
    J Pediatr Ophthalmol Strabismus; 2010 Aug; 47 Online():e1-4. PubMed ID: 21158371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dramatic regression of persistent tunica vasculosa lentis associated with retinopathy of prematurity following treatment with intravitreal bevacizumab.
    Goldman DR; Baumal CR
    J Pediatr Ophthalmol Strabismus; 2013 Jun; 50 Online():e27-9. PubMed ID: 24601434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.